Each sugar coated sustained release tablet contains:
Active ingredient:
Potassium chloride 600 mg eq.to potassium 315 mg
Sugar coated sustained release tablets .
Potassium, as the most abundant intracellular cation, plays an essential role in several important physiological functions, including transmission of nerve impulses, contraction of cardiac, skeletal, and smooth-muscle tissues, and maintenance of normal renal function. It also aids in the regulation of osmotic pressure and the acid-base.
Geo Pota-k 600 SR is indicated for the correction and/or prevention of hypokalaemia in those patients who cannot tolerate or refuse to take liquid or effervescent potassium chloride, or when there is a problem of compliance with these preparations. The following conditions may require potassium supplementation:
(I) inadequate dietary intake in cases either of poor dietary habits (elderly patients, severe alcoholics) or of malnutrition (starvation, excessive weight-reduction diet, anorexia nervosa).
(II) Increased gastro-intestinal potassium losses due to repeated vomiting, except in the case of pyloric stenosis (see "Contraindications"), diarrhea, villous adenomas, intestinal fistulae, chronic laxative abuse, and intestinal hyper motility.
(III) Increased renal potassium losses due to:
Prolonged intensive medication and/or high doses with the following drugs:
- K+ depleting diuretics, especially in patients with other factors states, congestive heart failure, or chronic liver disease (cirrhosis with ascites), and also in those who are receiving digitalis therapy or taking drugs which prolong the QT interval, as well as in patients with coronary artery disease and/or with cardiac arrhythmias. In these cases, diuretic treatment may change a subclinical hypokalaemia into a clinical condition with overt signs, such as ventricular ectopic activities.
- Corticosteroids, ACTH.
- Antibiotics such as carbencillin, gentamicin, clindamycin, amphotericin B.
- Carbenoxolone sodium.
- Primary (Conn's syndrome) or secondary hyperaldosteronism, including accelerated hypertension and Bartter's syndrome.
- Increased secretion of glucocorticoids (Cushing's syndrome).
- Renal tubular diseases (e.g. salt-wasting nephropathies, hereditary tubular disorders, leukemia with lysozymuria, Liddle's syndrome).
(IV) Altered transcellular shifts of potassium, as encountered in hypokalaemic familial periodic paralysis and in megaloblasic anaemia in the acute phase of the illness (as an adjunct to specific treatment
Adults
Depending on the patient's individual needs, a daily dosage of 2 – 3 sugar coated tablets (16 – 24 mmol K+) should generally prove sufficient for the prevention of hypokalaemia. When correcting hypokalaemia, doses of 40 – 60 up to 100 mmol K+ (corresponding to 5 – 6 up to 12 sugar-coated tablets) may be required, depending on the initial plasma K+ concentration. The response to the treatment should preferably be monitored by repeated determinations of plasma potassium, and Geo Pota-k 600 SR should be continued until the hypokalaemia has been corrected.
Children
Safety and effectiveness in children have not been established
- Hypersensivity to potassium administration, as found, for example, in adynamia episodic and congenital paramyotonia.
- All forms of hyperkalaemia, since a further increase in the serum potassium concentration in such patients can produce cardiac arrhythmia and cardiac arrest. Hyperkalaemia may complicate any of the following conditions: Marked renal failure, conditions involving intensive cell destruction (e.g. trauma, burns, massive haemolysis, rhabdomyolysis, rhabdomyolysis, and tumor lysis), untreated Addison's disease, hyporenimaemic hypoaldosteronism, as well as decompensate cases of metabolic acidosis and acute dehydration.
- Marked renal failure, even when it is not yet associated with manifest hyperkalaemia.
- Renal failure, even when it is not yet associated with manifest hyperkalaemia.
- Concomitant treatment with potassium-sparing diuretics (spironolactone, triamterene. Amiloride).
- Furthermore and as with all other sustained-release forms of potassium chloride, Geo Pota-k 600 SR is contra-indicated in any patient in whom there is cause for arrest or delay in tablet passage through the GIT. These states include:
- Partial or complete oesophageal, obstruction for example by carcinomas (oesophageal; post-cricoidal, thyroidal), aortic aneurysm left-atrial enlargement, inflammatory stricture due to reflux oesophagitis, and oesophageal displacement due to cardiac surgery (e.g. valve replacement).
- Stenosis or atony in any part of the GIT (e.g. pyloric stenosis, intestinal strictures).
Store at temperature, not exceeding 30 º C.
One geo pota k box: 22.5 EGP (30 TABLETS)
The Box : 3 strips each strip contains 10 tablets (7.5 EGP)
